文献速递膀胱癌与上尿路尿路上皮癌

瑞典1997至2014年未接受根治性治疗的限制于器官的肌层浸润性膀胱癌患者的全国性人群分析

A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014.
PubMed 文献 · J Urol · 2019-10-09

该研究基于瑞典膀胱癌数据库1997至2014年数据,分析9811例T2-T4期肌层浸润性膀胱癌患者,其中5592例未接受根治性治疗。中位总生存女性7个月劣于男性8个月,死亡风险因素包括更高肿瘤分期、年龄大于80岁、较晚诊断年份和女性。限制于器官疾病(T2-T3 M0)患者1352例(24%),中位总生存11个月。

要点

  • 未接受根治性治疗的肌层浸润性膀胱癌患者中位总生存男性8个月,女性7个月。
  • 死亡风险因素包括更高肿瘤分期、年龄大于80岁、较晚诊断年份和女性。
  • 限制于器官疾病患者占24%,中位总生存11个月,多数为N0期。

核心结论

  • 未接受根治性治疗的患者经历显著的疾病特异性并发症,在生命最后一年频繁住院,主要死于膀胱癌进展。

研究设计与样本

  • 基于瑞典膀胱癌数据库的全国性人群队列分析,纳入1997至2014年9811例T2-T4期患者。
  • 采用Kaplan-Meier法估计中位总生存和癌症特异性生存,Cox比例风险模型估计预后因素的相对风险。

主要发现

  • 5592例未接受根治性治疗的患者中68%为男性,32%为女性,中位年龄分别为79岁和81岁。
  • 这些患者1年后平均住院2.1次,平均住院18.8天,住院期间最常见的手术为泌尿外科大手术和小手术。
  • 中位总生存女性7个月劣于男性8个月。
  • 膀胱癌死亡风险因素为更高肿瘤分期、年龄大于80岁、较晚诊断年份和女性。
  • 限制于器官疾病(T2-T3 M0)患者1352例(24%),诊断后前12个月中位住院2.4次/人,半数住院归因于癌症或泌尿生殖系统症状,中位总生存11个月,多数为N0期,中位总生存较其他患者长2个月但其他结局相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While radical cystectomy remains the standard treatment of muscle invasive bladder cancer, the natural history of patients unable or unwilling to receive therapy with curative intent is not well understood. The study objective was to identify these patients in a population based cohort, investigate the clinical profile and describe time to mortality. MATERIALS AND METHODS: We analyzed the Bladder Cancer Data Base Sweden, a database collected from 1997 to 2014, and identified 9,811 patients with stage T2-T4 disease. Median overall and cancer specific survival was estimated by the Kaplan-Meier method. Relative risks due to prognostic factors were estimated using Cox proportional hazards models. RESULTS: Of the 5,592 patients who did not receive therapy with curative intent 68% were male and 32% were female with a median age of 79 and 81 years, respectively. After 1 year patients had been hospitalized an average of 2.1 times for an average of 18.8 days. Major and minor urological surgeries were the most commonly registered procedures during these hospitalizations. Median overall survival was worse in women than in men (7 vs 8 months). Risk factors for death from bladder cancer were higher tumor stage, age greater than 80 years, later year of diagnosis and female gender. Organ confined disease (T2-T3 M0) was diagnosed in 1,352 patients (24%). These patients had a median of 2.4 hospitalizations per patient during the first 12 months after diagnosis. Half of these hospitalizations were due to cancer or genitourinary symptoms. Median overall survival in the organ confined subgroup was 11 months. Most of these patients had stage N0 disease. They had 2-month longer median overall survival but otherwise similar outcomes. CONCLUSIONS: These patients experience substantial disease specific morbidity. They are hospitalized frequently during the final year of life and primarily die of bladder cancer progression.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Westergren DO, Gårdmark T, Lindhagen L, et al. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. J Urol. 2019. PMID: 31144594. doi:10.1097/JU.0000000000000350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。